EXAS
Exact SciencesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
EXAS Profile
Exact Sciences Corporation
A leading provider of cancer screening and diagnostic tests
Biological Technology
02/10/1995
01/30/2001
NASDAQ Stock Exchange
6,900
12-31
Common stock
5505 Endeavor Lane, Madison, WI 53719
--
Exact Sciences Corporation is a molecular diagnostic company focused on the early detection and prevention of colorectal cancer. The company was merged in Delaware on February 10, 1995, and has independent intellectual property rights for non-invasive molecular detection technology, which can detect precancerous lesions of colorectal cancer and colorectal cancer. The company's goal is to become a market leader in patient-friendly diagnostic screening products, producing products for colorectal cancer precancerous lesions and early detection of colorectal cancer. To achieve this goal, the company's strategic route includes the following points: research and development of products, through the clinical approval process of the US Food and Drug Administration (FDA); commercialization of FDA-approved products, detection of colorectal cancer precancerous lesions and colorectal cancer; and substantial product compensation from product payers.
